Fig. 4
Overview of cell sources and formats investigated in clinical trials. A The figure summarizes the sources from which the NK cells are derived. B Distribution of clinical trials based on whether the NK cells are administered as allogeneic or autologous products. C Cell sources distributed across the different disease groups, with increasing bubble size indicating higher frequency. iPSCs inducible pluripotent stem cells.